← Back to Search

Balance Improvement Intervention for Vestibular Hypofunction (MINDGAPS Trial)

N/A
Recruiting
Research Sponsored by University of Montana
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ability to stand independently
Be older than 18 years old
Must not have
History of peripheral or central oculomotor palsy
History of vertebral or carotid artery dissection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new intervention for improving vestibular function (balance) in older adults, to help prevent falls and other health problems.

Who is the study for?
This trial is for older adults who can stand on their own and have dizziness or balance problems due to vestibular hypofunction, confirmed by specific tests. It's not for those with blindness, neck spine disorders, certain artery issues, or eye movement problems caused by central nervous system dysfunction.
What is being tested?
The study is testing a new intervention designed to improve vestibular function and reduce dizziness in older adults living in the community. The research will evaluate how well it works, its safety and feasibility, and whether people are likely to use it regularly.
What are the potential side effects?
Since this is a pilot study focusing on a non-drug intervention for balance improvement, detailed side effects aren't specified but may include discomfort or increased dizziness during initial use of the system.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can stand up on my own.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had paralysis affecting my eye movement.
Select...
I have had a vertebral or carotid artery dissection.
Select...
I have had issues with my neck's bones.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Computerized Dynamic Visual Acuity (cDVA)
Secondary study objectives
Activities-specific Balance Confidence Scale (ABC)
Dizziness Handicap Inventory (DHI)
Functional Gait Assessment (FGA)
+3 more
Other study objectives
Community Ambulatory Task (CAT)
General Well Being Scale
Life Space Mobility Assessment (LSA)
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
361 Previous Clinical Trials
182,022 Total Patients Enrolled
1 Trials studying Vestibular Hypofunction
30 Patients Enrolled for Vestibular Hypofunction
Johns Hopkins UniversityOTHER
2,339 Previous Clinical Trials
14,881,595 Total Patients Enrolled
University of MontanaLead Sponsor
26 Previous Clinical Trials
3,292 Total Patients Enrolled
1 Trials studying Vestibular Hypofunction
500 Patients Enrolled for Vestibular Hypofunction

Media Library

Novel Intervention System Clinical Trial Eligibility Overview. Trial Name: NCT05391932 — N/A
Vestibular Hypofunction Research Study Groups:
Vestibular Hypofunction Clinical Trial 2023: Novel Intervention System Highlights & Side Effects. Trial Name: NCT05391932 — N/A
Novel Intervention System 2023 Treatment Timeline for Medical Study. Trial Name: NCT05391932 — N/A
~2 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top